Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Prostatic Neoplasms × Circulating Tumor DNA × Clear all

Status

Sponsor Class

Study Type

Observational 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Glioblastoma 2 Colorectal Neoplasms 2 Vulvar Neoplasms 1 Urinary Bladder Neoplasms 1 Stomach Neoplasms 1 Prostatic Neoplasms 1 Oropharyngeal Neoplasms 1 Neoplastic Cells, Circulating 1 Neoplasm, Residual 1 Melanoma 1 Locally Advanced Rectal Carcinoma 1 Hypoxia 1 Gliosarcoma 1 Glioma 1 Genetic Diseases, Inborn 1 Esophageal Neoplasms 1 Circulating Tumor DNA 1 Carcinoma, Non-Small-Cell Lung 1 Biliary Tract Neoplasms 1 Astrocytoma 1

Interventions

Docetaxel 155 Magnetic Resonance Spectroscopy 130 Radiotherapy 127 Prednisone 101 Leuprolide 101 Radiosurgery 94 enzalutamide 93 Androgen Antagonists 84 Abiraterone Acetate 83 Goserelin 74 bicalutamide 70 gallium 68 PSMA-11 61 apalutamide 53 Surveys and Questionnaires 53 Specimen Handling 53 acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 52 Radiation 44 Biopsy 42 Gonadotropin-Releasing Hormone 41 Brachytherapy 41 Standard of Care 38 abiraterone 37 Blood Specimen Collection 35 darolutamide 34 cabazitaxel 34 Exercise 33 Radiotherapy, Intensity-Modulated 32 Carboplatin 32 Triptorelin Pamoate 29 Pluvicto 28

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05702619 2023-01-27

HYPROGEN

The Christie NHS Foundation Trust

Hypoxia, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡